[
  {
    "ts": null,
    "headline": "Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III",
    "summary": "SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.",
    "url": "https://finnhub.io/api/news?id=df934dbef5ec355bc69edf04babbaa5da6fcd2fb61cdca2c9c61efb18d650a36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734975720,
      "headline": "Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III",
      "id": 132123072,
      "image": "https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.",
      "url": "https://finnhub.io/api/news?id=df934dbef5ec355bc69edf04babbaa5da6fcd2fb61cdca2c9c61efb18d650a36"
    }
  },
  {
    "ts": null,
    "headline": "Should Value Investors Buy Pfizer (PFE) Stock?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=ad016e7e585134274d6d5e9de991e6e32e37f6872093637cda1055722e8bf692",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734964815,
      "headline": "Should Value Investors Buy Pfizer (PFE) Stock?",
      "id": 132120776,
      "image": "https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=ad016e7e585134274d6d5e9de991e6e32e37f6872093637cda1055722e8bf692"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=7228b53e481f7964e033516a222b13f20535c145c422d28011dd73bc6aaea91a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734962415,
      "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
      "id": 132120777,
      "image": "https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=7228b53e481f7964e033516a222b13f20535c145c422d28011dd73bc6aaea91a"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=88c1ebdd346f4306254e3ccf3bb3703489bd731eabd078564e0df900817876aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734962405,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 132120108,
      "image": "https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=88c1ebdd346f4306254e3ccf3bb3703489bd731eabd078564e0df900817876aa"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA Approves Pfizer's BRAFTOVI Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer",
    "summary": "NEW YORK - Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved BRAFTOVI in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic...",
    "url": "https://finnhub.io/api/news?id=c28aa4b14ac778a5bd0bb60131cd846eb2716261a37fd058b81e29177e4f86a4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734953209,
      "headline": "U.S. FDA Approves Pfizer's BRAFTOVI Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer",
      "id": 132120303,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "NEW YORK - Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved BRAFTOVI in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic...",
      "url": "https://finnhub.io/api/news?id=c28aa4b14ac778a5bd0bb60131cd846eb2716261a37fd058b81e29177e4f86a4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA",
    "summary": "The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.",
    "url": "https://finnhub.io/api/news?id=97ec7d11705990165dfc8cb5a71f70667328b4a51fb42fe6f98e2a9abb00dd91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734952836,
      "headline": "Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA",
      "id": 132117532,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Pharma-1-Pfizerr-Shutterstock_2322931915.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.",
      "url": "https://finnhub.io/api/news?id=97ec7d11705990165dfc8cb5a71f70667328b4a51fb42fe6f98e2a9abb00dd91"
    }
  },
  {
    "ts": null,
    "headline": "Stocking Stuffers for Income Investors: 3 Ultra-High-Yield Dividend Stocks to Buy Before the End of 2024",
    "summary": "Are there potential stocking stuffers for income investors?  Enterprise Products Partners (NYSE: EPD) operates over 50,000 miles of pipelines that transport natural gas liquids (NGLs), natural gas, crude oil, and petrochemicals across the U.S. The limited partnership (LP) also owns many other midstream energy assets, including storage facilities that hold over 300 million barrels of liquids and 42 natural gas processing trains.  As an LP, Enterprise Products Partners pays a distribution to unitholders rather than a dividend to shareholders.",
    "url": "https://finnhub.io/api/news?id=066043699ea7a214ae17a0625b26ce5c2e980ed3ed4ba5ee712d040872791fa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734951000,
      "headline": "Stocking Stuffers for Income Investors: 3 Ultra-High-Yield Dividend Stocks to Buy Before the End of 2024",
      "id": 132117534,
      "image": "https://g.foolcdn.com/editorial/images/801776/christmas-stocking-smiling-person.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Are there potential stocking stuffers for income investors?  Enterprise Products Partners (NYSE: EPD) operates over 50,000 miles of pipelines that transport natural gas liquids (NGLs), natural gas, crude oil, and petrochemicals across the U.S. The limited partnership (LP) also owns many other midstream energy assets, including storage facilities that hold over 300 million barrels of liquids and 42 natural gas processing trains.  As an LP, Enterprise Products Partners pays a distribution to unitholders rather than a dividend to shareholders.",
      "url": "https://finnhub.io/api/news?id=066043699ea7a214ae17a0625b26ce5c2e980ed3ed4ba5ee712d040872791fa5"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Equity Income Fund Q3 2024 Commentary",
    "summary": "Hartford Equity Income Fund (I Share) underperformed the Russell 1000 Value Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=4490c5102366252755ca7a7f6f527f692cd256f570bb1f2f364a69ee5c8fa307",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734947160,
      "headline": "Hartford Equity Income Fund Q3 2024 Commentary",
      "id": 132119127,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2095584352/image_2095584352.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Hartford Equity Income Fund (I Share) underperformed the Russell 1000 Value Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=4490c5102366252755ca7a7f6f527f692cd256f570bb1f2f364a69ee5c8fa307"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: FDA approves cancer treatment",
    "summary": "The U.S. FDA approves Pfizer's BRAFTOVI® combination regimen as a first-line treatment for BRAF V600E-mutated metastatic colorectal cancer.The indication was approved on the basis of a statistically...",
    "url": "https://finnhub.io/api/news?id=cf5dccb5b0da7cdffdbfca6a1cbfc3c6b3d5fcb124418987f93f2f1539c2a282",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734926413,
      "headline": "Pfizer: FDA approves cancer treatment",
      "id": 132116413,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. FDA approves Pfizer's BRAFTOVI® combination regimen as a first-line treatment for BRAF V600E-mutated metastatic colorectal cancer.The indication was approved on the basis of a statistically...",
      "url": "https://finnhub.io/api/news?id=cf5dccb5b0da7cdffdbfca6a1cbfc3c6b3d5fcb124418987f93f2f1539c2a282"
    }
  }
]